Porter DL, Levine BL, Kalos M, Bagg A, June CH Delayed tumor lysis and CLL remission from chimeric antigen receptor modified T cells , New England Journal of Medicine, 365: 2011,725-733
Reshef R, Luger S, Hexner EO, Loren AW, Frey NV, Nasta SD, Goldstein SC, Stadmauer EA, Smith J, Bailey S, Mick R, Heitjan DF, Emerson SG, Hoxie JA, Vonderheide RH, Porter DL. Blockade of Lymphocyte Chemotaxis in Visceral Graft-versus-Host Disease , New England Journal of Medicine, 367: 2012,135-145
Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH. T cells expressing chimeric receptors establish memory and potent antitumor effects in patients with advanced leukemia , Science Translational Medicine, 3: 2011,95ra73
Anasetti C, Logan BR, Lee SJ, Waller EK, Weisdorf DJ, Wingard JR, Cutler CS, Westervelt P, Woolfrey A, Couban S, Ehninger G, Johnston L, Maziarz RT, Pulsipher MA, Porter DL, Mineishi S, McCarty JM, Khan SP, Anderlini P, Bensinger WI, Leitman SF, Rowley SD, Bredeson C, Carter SL, Horowitz MM, Confer DL. Peripheral blood stem cells versus bone marrow from unrelated donors: results of Blood and Marrow Transplant Clinical Trials Network protocol 0201, a phase III, prospective, randomized trial. , New England Journal of Medicine, 367: 2012,1487-1496
Porter DL, Alyea EP, Antin JH, DeLima M, Estey, E, Falkenburg JHF, Hardy N, Kroeger N, Leis J, Levine J, Maloney DG, Peggs K, Rowe JM, Wayne AS, Giralt S, Bishop MR, van Besien K. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. , Biol Blood and Marrow Transplant, 16: 2010,1467-1503
Tizon R, Frey N, Heitjan DF, Tan KS, Goldstein SC, Hexner EO, Loren A, Luger SM, Reshef R, Tsai D, Vogl D, Davis J, Vozniak M, Fuchs B, Stadtmauer EA, Porter DL. High dose corticosteroids with or without etanercept for the treatment of idiopathic pneumonia syndrome after allogeneic SCT. , Bone Marrow Transplant, 47: 2011,1332-1337
Rager A, Frey N, Goldstein SC, Reshef R, Hexner EO, Loren A, Luger SM, Perl, A, Tsai D, Davis J, Vozniak M, Smith J, Stadtmauer EA, Porter DL. Inflammatory Cytokine Inhibition with Combination Daclizumab and Infliximab for Steroid Refractory Acute Graft-Versus-Host Disease , Bone Marrow Transplantation, epub: 2010
Paralkar VR, Nasta SD, Morrissey K, Smith J, Vassilev P, Martin ME, Goldstein SC, Loren A, Rook AH, Kim EJ, Porter DL. Allogeneic hematopoietic stem cell transplantation for primary cutaneous T cell lymphomas , Bone Marrow Transplantation, 47: 2012,940-945
Rager A, Porter DL Cellular therapy following allogeneic stem cell transplantation , Therapeutic Advances in Hematology, 2(6): 2011,416 - 435.
Goldstein SC, Porter DL Allogeneic immunotherapy to optimize the graft-versus tumor effect: concepts and controversies. , Expert Review of Hematology, 3(3): 2010,301-314
